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Abstract
Background: Atrial fibrillation is the commonest arrhythmia which raises the risk of heart failure, thromboembolic
stroke, morbidity and death. Pharmacological treatments of this condition are focused on heart rate control, rhythm
control and reduction in risk of stroke. Selective ablation of cardiac tissues resulting in isolation of areas causing
atrial fibrillation is another treatment strategy which can be delivered by two minimally invasive interventions:
percutaneous catheter ablation and thoracoscopic surgical ablation. The main purpose of this trial is to compare
the effectiveness and safety of these two interventions.
Methods/design: Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial
Fibrillation (CASA-AF) is a prospective, multi-centre, randomised controlled trial within three NHS tertiary cardiovascular
centres specialising in treatment of atrial fibrillation. Eligible adults (n = 120) with symptomatic, long-standing,
persistent atrial fibrillation will be randomly allocated to either catheter ablation or thoracoscopic ablation in a 1:1 ratio.
Pre-determined lesion sets will be delivered in each treatment arm with confirmation of appropriate conduction block.
All patients will have an implantable loop recorder (ILR) inserted subcutaneously immediately following ablation to
enable continuous heart rhythm monitoring for at least 12 months. The devices will be programmed to detect
episodes of atrial fibrillation and atrial tachycardia ≥ 30 s in duration. The patients will be followed for 12 months,
completing appropriate clinical assessments and questionnaires every 3 months. The ILR data will be wirelessly
transmitted daily and evaluated every month for the duration of the follow-up. The primary endpoint in the study is
freedom from atrial fibrillation and atrial tachycardia at the end of the follow-up period.
Discussion: The CASA-AF Trial is a National Institute for Health Research-funded study that will provide first-class
evidence on the comparative efficacy, safety and cost-effectiveness of thoracoscopic surgical ablation and conventional
percutaneous catheter ablation for long-standing persistent atrial fibrillation. In addition, the results of the trial will
provide information on the effects on patients’ quality of life.
Trial registration: ISRCTN Registry, ISRCTN18250790. Registered on 24 April 2015.
Keywords: Long-standing persistent atrial fibrillation, Catheter ablation, Thoracoscopic surgical ablation, Randomised
clinical trial, Implantable loop recorder, Left atrial appendage exclusion
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Background
Atrial fibrillation (AF) is the most common arrhythmia,
characterised by an irregularly irregular pulse, loss of
atrial contractile function and attendant loss of active
ventricular filling. It is an important public health con-
cern because it affects 1–2% of the population. Further-
more, its prevalence is on the increase and is likely to
continue to rise with an aging population [1–5]. AF is
associated with lower quality of life, increased morbidity
(5-fold increase in thromboembolic stroke, 3-fold in-
crease in heart failure) and mortality (2-fold increased
fatality) and results in a large number of hospital admis-
sions [4–8]. AF treatment is usually lifelong and costly,
resulting in considerable burden on national health re-
sources. Some estimates suggest that AF accounts for ~ 2%
of the NHS budget in the United Kingdom [2, 8–10].
Stroke prevention with anticoagulants is the cornerstone
in management of patients with AF. Additionally, pharma-
cological agents for heart rhythm or rate control may be
used, depending on clinical indications and patient char-
acteristics. Rhythm control is preferred in patients with
persistent AF who continue to experience limiting symp-
toms despite adequate rate control [2, 5, 11, 12].
Traditionally, rhythm control is attempted with anti-
arrhythmic drugs (AADs) and/or direct current (DC)
cardioversion, but the long-term efficacy of this ap-
proach is poor and is associated with drug side effects
and risk of pro-arrhythmia. Percutaneous catheter abla-
tion has been shown to be more effective than AAD
therapy in achieving and maintaining normal sinus
rhythm (SR) [4, 5, 11–18] and is now routinely offered
as standard management of patients with symptomatic
AF [2, 5, 12].
Conventional catheter ablation can reliably maintain
SR in a large proportion of patients with paroxysmal AF
(up to 78%) [8, 12, 19–22] and in a majority of patients
with short-lasting persistent AF [23–27]. However, its
success rate in maintaining SR in patients with long-
standing persistent atrial fibrillation (LSPAF) is poor at
only 32–40%, with frequent requirement of more than
one procedure to increase success rates [8, 28–32].
Minimally invasive thoracoscopic surgical ablation
provides another option for treatment of AF, and there
are indications that it may be more effective than
catheter ablation in restoring SR due to direct access
and ability to execute transmural and contiguous lesions,
ganglionic plexi ablation and ability to excise left atrial
appendage (LAA) [33–36]. Any surgical procedure
carries a risk of morbidity and complications, but risks
associated with thoracoscopic surgical ablation have not
been directly compared with catheter ablation.
In this trial, we will compare the effectiveness of the
two procedures in maintaining freedom from arrhythmia
in patients with LSPAF, with the associated effect on
quality of life. We will also examine the complications
associated with each ablation technique, as well as their
cost-effectiveness.
Methods/design
CASA-AF is a prospective, multicentre, randomised clinical
trial designed to assess the effectiveness, safety and cost-
effectiveness of thoracoscopic surgical ablation compared
with catheter ablation (usual care) in patients with LSPAF.
It is on-going within three tertiary specialist NHS hospitals
in England with proven expertise in both interventions and
a large pool of potentially eligible participants (Royal
Brompton Hospital, Harefield Hospital, and Liverpool
Heart and Chest Hospital).
This protocol follows the guidance of Standard Proto-
col Items: Recommendations for Interventional Trials
(SPIRIT) 2013 statement [37, 38], and it includes the
schedule of enrolment and relevant assessments (Figs. 1
and 2) based on the SPIRIT figure template. A com-
pleted SPIRIT checklist is provided in Additional file 1.
Outcomes of the study
Primary
The main objective of this trial is to identify the most
effective ablative intervention for treating LSPAF. The
primary hypothesis is that thoracoscopic surgical ablation is
more effective than percutaneous catheter ablation in
achieving freedom from atrial arrhythmia. The primary out-
come in the study is therefore freedom from arrhythmia
after a single ablation procedure and without AADs during
study follow-up (starting from the end of the blanking
period of 3 months, up to 12 months after the ablation).
Data collected by the implantable loop recorder (ILR) over
the follow-up period will be used to detect the recurrence
of AF/atrial tachycardia (AF/AT) ≥ 30 s.
Secondary
The most important among the secondary outcomes is
the safety of the two interventions. The safety endpoint
in this trial is intervention-related major complication,
defined as permanent injury or death, one that requires
unplanned intervention for treatment, or one that pro-
longs or requires unplanned hospitalisation for > 48 h.
In addition, we will evaluate the following:
 Secondary efficacy outcome, defined as freedom from
atrial arrhythmias following multiple procedures
without AADs during 12 months of follow-up
 The clinical success of the two interventions by
comparing reduction of AF burden (≥ 75%) over the
follow-up period in each treatment arm
 Changes in atrial size and function following
ablation using echocardiography and cardiac
magnetic resonance imaging (cMRI) parameters
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 The effects of arrhythmia interventions on patients’
symptoms and quality of life through changes in
European Heart Rhythm Association (EHRA),
EuroQol standardised health questionnaire (EQ-5D-5L)
and Atrial Fibrillation Effect on QualiTy-of-Life
Questionnaire (AFEQT) scores [39, 40]
 Quality-adjusted life-years (QALYs) accrued during
the 12-month study period
 Cost-effectiveness (incremental cost per QALY
gained) for surgical ablation compared with catheter
ablation estimated over the 12-month study period
(‘within-trial’ analysis) and over a lifetime horizon
(estimated by modelling)
Characteristics of participants
Adults with symptomatic LSPAF considered for treatment
(DC cardioversion or catheter ablation) at the participating
trial centres will be considered for inclusion in the study.
The complete list of inclusion and exclusion criteria is
presented in Table 1.
The consultant cardiologists at participating sites will
refer patients they identify in the outpatient clinics or
through DC cardioversion and ablation waiting lists for
inclusion in the trial. The aim is to continue screening
until the required number of participants (n = 120) has
been allocated to treatment. Patients can withdraw from
the study at any time in the follow-up period and will
not be replaced, because levels of attrition have formed
part of the sample size calculation.
CASA-AF trial schedule
Patients considered eligible to take part in the study will be
provided with a participant information sheet and given op-
portunities to discuss details of potential participation with
the study team. They will be encouraged to discuss the in-
formation with their family, friends and general practitioners
before making a decision to participate in the trial. When
Fig. 1 Schematic representation of Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF) study
design. AAD Anti-arrhythmic drug, AF Atrial fibrillation, AFEQT Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire, AT Atrial tachycardia, cMRI Cardiac
magnetic resonance imaging, DC Direct current, ECG Electrocardiogram, EHRA European Heart Rhythm Association, EQ-5D-5L EuroQol standardised health
questionnaire, HEQ Health economics questionnaire, ILR Implantable loop recorder, TTE Transthoracic echocardiogram
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they confirm their interest in taking part, a hospital appoint-
ment will be arranged for them to sign an informed consent
form and to complete baseline assessments. Participants’
progress through the study is shown schematically in Fig. 1.
Baseline study visit
As part of the baseline visit, we will collect blood samples
for routine haematology, biochemistry and coagulation
assessments as well as samples for cardiac biomarker
evaluation. With patients’ permission, surplus samples will
be stored for future research by biobanks at the par-
ticipating centres (Cardiovascular Biomedical Research
Unit Biobank at the Royal Brompton and Harefield
NHS Trust and the Liverpool Bio-Innovation Hub
Biobank associated with Liverpool Heart and Chest
Hospital NHS Trust).
Fig. 2 Schedule of enrolment, tests and assessments in the Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial
Fibrillation (CASA-AF) study (Standard Protocol Items: Recommendations for Interventional Trials [SPIRIT] figure). AF Atrial fibrillation, AFEQT Atrial Fibrillation
Effect on QualiTy-of-Life Questionnaire, CHA2DS2VASc score Congestive heart failure (or left ventricular systolic dysfunction), hypertension (blood pressure
consistently > 140/90 mmHg or treated hypertension on medication), age≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack or
thromboembolism, vascular disease (e.g., peripheral artery disease, myocardial infarction, aortic plaque), age 65–74 years, sex category (i.e., female sex), DC
Direct current, EHRA European Heart Rhythm Association, EQ-5D-5 L EuroQol standardised health questionnaire, FUP Follow-up, HAS-BLED score Hypertension,
abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly, drugs/alcohol concomitantly, ILR
Implantable loop recorder, LSPAF Long-standing persistent atrial fibrillation
Khan et al. Trials  (2018) 19:117 Page 4 of 12
Routine haematology and biochemistry assessments
include full blood count, electrolytes, renal function
tests, coagulation profile, liver function tests, thyroid
function tests, C-reactive protein, tests for diabetes
(haemoglobin A1C) and lipid profile (high-density lipopro-
tein, low-density lipoprotein). Transthoracic echocardio-
gram (TTE) and cMRI assessment will ensure that patients
do not have poor left ventricular (LV) function, valvular dis-
ease or other pathologies that meet the exclusion criteria.
Additional clinical and study data collected at baseline, as
well as at other study time points, are shown in Fig. 2
(SPIRIT figure). A detailed study codebook contains a
complete list of all the variables, including type of data and
reference values where appropriate.
Treatment allocation
Patients with confirmed eligibility for participation at
baseline assessments will proceed to being assigned to
treatment group by computer-generated sequence in a
1:1 ratio using minimisation. A secure 24-h bespoke
web-based system hosted by the King’s Clinical Trials
Unit provides named research team members with
access to the allocation system where they enter each
participant’s unique participant identification number,
initials and date of birth in an electronic online form. In
addition, the system uses the study site code, participant’s
sex and the size of the left atrium (< 50 mm, > 50 mm) as
stratifying variables. Allocation is concealed, but blinding
is not possible in this trial. However, the primary outcome
assessor will be blinded to treatment arms.
Pre-ablation
Anticoagulation According to current guidelines [2, 9,
41–44], it is recommended that patients randomised to
catheter ablation remain on uninterrupted warfarin
treatment unless a different strategy is outlined by the
operator. If patients are treated with novel oral anticoag-
ulants (NOACs), they can be converted to warfarin
treatment for 4 weeks before the catheter ablation
procedure, continue with NOACs or stop the therapy
24–36 h before the ablation procedure, depending on
the type of NOAC and clinician’s preference. For
patients randomised to surgical ablation, it is current
practice to stop warfarin therapy 5 days before the pro-
cedure and have anticoagulation bridging with enoxa-
parin at a dose of 1.5 mg/kg once daily for 3 days with
no anticoagulation 1 day before they have the procedure.
NOAC treatment will also be discontinued for patients
randomised to surgical ablation. The timing of discon-
tinuation will depend on the type of drug and renal
function, but in general NOACs will be stopped 2–5 days
before surgery. Anticoagulation protocols may be altered
as guidelines are updated and local practices change.
Ablation procedures
Thoracoscopic surgical AF ablation Details of the
operation have been described previously by Yilmaz and
others [45–47]. In this trial the protocol additionally
mandates the presence of a cardiac electrophysiologist in
theatre during surgical ablation to ensure that conduc-
tion block is tested and achieved for all lesions, because
this has been associated with a trend towards better out-
comes [48]. Cardiac surgeons participating in this study
need to be experienced in video-assisted thoracoscopic
surgery and to have conducted at least 20 thoracoscopic
ablations for AF as the primary operator.
Transoesophageal echocardiography (TOE) will be
performed with the patient under general anaesthesia to
exclude left atrial (LA) thrombus prior to the start of the
procedure. Three thoracoports will be introduced on
each side. Pulmonary veins (PVs) and LA antrum will be
exposed by pericardiotomy and blunt dissection using a
Lumitip™ dissector (AtriCure, Inc., West Chester, OH,
USA) into the transverse and oblique sinuses. Pulmonary
vein isolation (PVI) will be performed from the epicardial
surface using a bipolar radiofrequency ablation clamp
(AtriCure, Inc.) and overlapping applications around the
LA antrum. PVI will be confirmed at the end of the pro-
cedure by testing for entrance and exit block during
pacing on both sides of the lesion in SR. Further ablation
Table 1 Eligibility criteria in Catheter Ablation versus Thoracoscopic
Surgical Ablation in Long Standing Persistent Atrial Fibrillation trial
Inclusion criteria
Age≥ 18 years
Long-standing persistent AF (> 12 months’ duration)
EHRA symptom score > 2 (see Additional file 1)
Left ventricular ejection fraction ≥ 40%
Suitable for either ablation procedure
Exclusion criteria
Valvular heart disease with severity greater than mild
Contraindication to anticoagulation
Thrombus in the left atrium despite anticoagulation in therapeutic range
Cerebrovascular accident within the previous 6 months
Previous thoracic or cardiac surgery (including surgical interventions for AF)
Prior left atrial catheter ablation for AF
Unable to provide informed written consent
Active malignancy, another severe concomitant condition or presence
of implanted cardiac devices that would preclude patient undergoing
study-specific procedures
Pregnant or breastfeeding, or women of childbearing age not using a
reliable contraceptive method
AF Atrial fibrillation, EHRA European Heart Rhythm Association
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will be performed if PVI is incomplete. An Isolator multi-
functional pen (AtriCure) will then be used to ablate gangli-
onic plexi located by high-frequency stimulation. Additional
linear lines will be undertaken using the multifunctional pen
(AtriCure) connecting the contralateral superior PVs (roof
line) and the inferior PVs (inferior line) to create a posterior
wall box lesion. If AF persists, the SR will be restored by
external DC cardioversion. Sensing and pacing manoeuvres
will then be used to verify electrical isolation of the posterior
box in SR. The LAA will then be excluded using the
AtriClip® LAA excluder system (AtriCure) owing to recent
emerging evidence of improved outcomes with LAA exclu-
sion mechanically and electrical isolation [49–52]. The ILR
will be implanted at the end of the procedure, and patients
will be extubated in the operating theatre.
Catheter AF ablation (usual care treatment) TOE will
exclude LA thrombus under general anaesthesia and
guide trans-septal puncture. Patients will be heparinised
to maintain an activated clotting time (ACT) between
300 and 350 s. The CARTO 3 three-dimensional electro-
anatomical mapping system (Biosense Webster, Irvine,
CA, USA) will be used to create the LA geometry with a
20-pole circular mapping catheter (LASSO 2515 NAV;
Biosense Webster). Simultaneous voltage maps will be
created using the CARTO® CONFIDENSE™ software
module. The voltage maps will be created in AF and in
SR once the patient is cardioverted. This will allow for
atrial low-voltage comparison to LA fibrosis captured by
cMRI. Ablation will be conducted with THERMACOOL®
SMARTTOUCH™ 3.5-mm irrigated-tip catheter (Biosense
Webster). A stepwise ablation strategy will be used to
electrically isolate the PVs at the antral level, then linear
ablation will be performed at the LA roof along with cre-
ation of a posterior line (to create a ‘box lesion’). A lateral
mitral isthmus line will be performed, and, finally, ablation
at the cavotricuspid isthmus ablation will be performed.
Electrical isolation of the PVs will be confirmed through
testing for both entrance and exit blocks with the circular
sensing catheter. The integrity of the linear lesions will be
assessed by differential pacing manoeuvres. If block is not
achieved, further ablation will be performed to achieve bi-
directional block across the linear lesions. If AT occurs at
any point, it will be mapped and ablated when possible
[53]. An ILR will be implanted at the end of the procedure
once the ACT has normalised following heparin reversal
with intravenous protamine. Patients will then be extu-
bated in the cardiac catheterisation laboratories.
Post-operative management
The patients will be managed post-operatively accord-
ing to standardised hospital protocols described
briefly below.
Post-operative analgesia Participants in the surgical abla-
tion arm will receive intercostal nerve block at each port
site (bupivacaine or similar agents; dosage depending on
patient characteristics and tolerance), paracetamol (1 g four
times daily intravenously or per rectum and then by
mouth) and codeine (30–60 mg up to four times daily). Pa-
tients can also be given tramadol (50 mg intramuscularly) if
appropriate. In the first 24 h post-procedure the patient will
be receiving patient-controlled analgesia with fentanyl or
morphine or other opioids, depending on the anaesthetist’s
recommendations and current clinical practice. Opiates
should be reduced 12 h post-operatively.
One day after surgery, if patients have normal renal func-
tion and are able to tolerate oral medication, analgesia
could be provided by non-steroidal anti-inflammatory
drugs for 1 week with or without opiates. On discharge, the
patients will have a supply of analgesics for 28 days to be
taken as needed. Participants in the catheter ablation arm
will be treated with paracetamol and codeine as required.
Post-operative anticoagulation After a minimum of
3 h following ablation, patients will receive anticoagula-
tion if there are no contraindications. Anticoagulation in
the surgical group will be achieved by using enoxaparin
(1.5 mg/kg once daily) or other heparin derivatives to
ensure rapid reversal if needed. Once chest drains are
removed, the patient’s usual anticoagulation (warfarin or
NOAC) will be restarted. Anticoagulation in the catheter
group will continue uninterrupted in normal routine.
Anticoagulation therapy will continue for the duration
of the trial follow-up.
Post-operative AADs AAD therapy (flecainide, procain-
amide, amiodarone or sotalol) will continue for a max-
imum of 3 months (blanking period) after the ablation
procedure, at which point it should be terminated. Drugs
that may have an effect on heart rhythm but are used to
treat other conditions such as hypertension will continue
to be administered as clinically indicated (i.e., β-blockers
and non-dihydropyridine calcium channel blockers).
Post-operative antibiotic prophylaxis In both treat-
ment arms patients will usually receive one dose of anti-
biotic on induction of anaesthesia, one dose at the end
of the procedure, and usual dose individual antibiotics
for 5 days post-operatively, depending on local practices.
Early post-operative discharge period Following dis-
charge, study participants will be contacted by the research
team once per week for the first month to assess their health
status. They will be asked about pain management, cough,
raised temperature, difficulties swallowing and any other
symptoms that may be early indications of possible compli-
cations. In addition, patients will be advised to contact the
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study team if they have any concerns regarding their health
for the duration of the study. If deemed appropriate the
patients will be brought back to the study centre for full
assessment, evaluation and treatment of health issues, even
if the likelihood of those issues being related to study proce-
dures is remote.
Implanted loop recorder The Medtronic Reveal LINQ
ILR (Medtronic, Minneapolis, MN, USA) will be used to
monitor and assess patients’ heart rhythm. The device is
highly sensitive and programmable to detect the occur-
rence of AF and AT lasting ≥ 30 s [54, 55]. Programming
parameters of the device are summarised in Table 2.
The patients are registered on the Medtronic CareLink®
Network following ILR insertion and instructed on how to
perform manual data downloads using their home moni-
toring equipment. Data from the ILRs are uploaded to the
CareLink® server over mobile phone networks. Patients
are asked to perform manual data downloads once per
week or more frequently, depending on the burden of
collected data in individual cases.
Named study team members are granted access to the
CareLink® Network server to monitor ILR data uploads for
their patients. A dedicated cardiac physiologist, blinded to
treatment allocation, analyses downloaded data on a regular
basis to produce monthly heart rhythm assessment reports
for each patient. A panel of three experts is nominated to
adjudicate in cases where heart rhythm is assessed as
ambiguous by the cardiac physiologist.
Follow-up schedule
Details of the assessments during study participation are
given in Fig. 2 as per SPIRIT 2013 recommendations.
Recurrence of symptomatic AF during the blanking
period (up to 3 months following ablation) will be
treated with DC cardioversion with or without use of
AADs, depending on patient tolerance and comorbidi-
ties. Patients will be offered percutaneous catheter abla-
tion if the AF recurs at a later point in the follow-up
period as shown in Fig. 1.
Data
Data collection and management
Source data worksheets and electronic case report forms
(eCRFs) have been designed with input from the chief
investigator (CI), principal investigator, study statistician
and relevant co-applicants. Paper source data worksheets
will be used for each patient to collect appropriate study
data, and these will then be transcribed into the eCRF
database. Trained individuals at each trial centre are
named on the delegation of duties log as responsible for
data collection and entry on the eCRF. Source data
worksheets will be reconciled at the end of the trial with
patients’ NHS medical notes in the recruiting centre.
The InferMed MACRO® database system (Elsevier,
Amsterdam, the Netherlands) was used to create the
eCRF, and it will be used to manage anonymised study
data. It has programmable referential data rules and
range checks to ensure data integrity at the time of data
entry. Any data edits can be monitored through database
audit trails, and the security is enforced by individual
logins and passwords. This system is hosted and main-
tained on a secure dedicated server by the King’s Clinical
Trials Unit.
Adverse events/serious adverse events
All adverse events (AEs) occurring during the course of
the trial will be collected, documented and recorded by
the research team at each trial centre. Patients are ad-
vised to contact the research team if they have any
health concerns during the study follow-up and will be
prompted to report those at every study visit.
The research teams will ensure that known complica-
tions as well as unexpected events/reactions are detailed
in patients’ study files as well as their medical notes. The
teams will follow an agreed protocol for timely reporting
of serious adverse events (SAEs), which involves written
notification to the chief investigator and the study spon-
sor as soon as possible. A list of expected complications
of the ablative procedures is shown in Table 3.
Recurrence of AF and subsequent hospital admission
for DC cardioversion or percutaneous catheter ablation
will not be treated as SAEs in the trial, but will be
recorded and reported with the results.
Data from imaging modalities and questionnaires
cMRI will be performed during the baseline visit and
again at 6 months after the ablation. It will be used to
capture LA area and length [56, 57] and to calculate
maximum and minimum LA volumes as well as the
cross-sectional diameter of PVs. The images will be
acquired using planes in the LV long- and short-axis
stacks. A specific protocol of sequences for late gadolinium
enhancement (LGE) of the LA will be used to evaluate
location and quantification of LA scars [58]. The LV
Table 2 Programming parameters for Reveal LINQ™ implantable
loop recorder
Programming feature Parameter programmed Duration
Indication After AF ablation
AT/AF Both ‘on’
AT Rates ≥ 100 /minutes
Tachycardia > 162 /minutes 48 beats
Asystole 4.5 s
Bradycardia < 40/min 8 beats
Patient symptom capture 7.5 min 4 episodes
AF Atrial fibrillation, AT Atrial tachycardia
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function will also be measured by volume quantification in
systole and diastole using endocardial tracing [59–61].
TTEs will be performed at baseline, 3 months after the
ablation and at the last study visit (12 months after the
ablation). In addition to the standard clinical protocol
set out by British Society of Echocardiography, we will
acquire images to allow for offline assessment of LA
function (measurement of myocardial velocities, LA
strain and strain rate) by using tissue Doppler and 2D
speckle-tracking methods [62–64].
The EHRA symptoms score and AFEQT and EQ-5D-5L
questionnaires will be used at each study visit to assess any
changes in patients’ symptoms and quality of life from base-
line to the end of the follow-up period [39, 65, 66]. We have
also designed a health economics questionnaire to collect
patient-reported data on the use of primary, secondary and
community health and social care services following abla-
tion to estimate costs.
Monitoring
An independent data monitoring committee (DMC)
consisting of four members (two cardiologists, a surgeon
and a statistician) has been established, with functions
and responsibilities detailed in a DMC charter. The
DMC meets at least twice annually and communicates
their advice to the trial steering committee (TSC).
The TSC has executive power and consists of seven
members, five of whom are independent (two cardiologists,
one surgeon and two lay members). This committee will
meet twice annually for the duration of active patient
recruitment and follow-up, and additional ad hoc meetings
may also be scheduled if necessary. This group’s functions
and remit are defined in the TSC charter. Two external
independent groups of experts specialising in electrophysi-
ology, cardiology and thoracic surgery will be formed to
evaluate primary and safety endpoints of the trial.
Statistical analyses
All statistical analyses will be based on intention to treat,
and the data analysed will be derived from all randomised
participants. We will also perform sensitivity analyses to
explore the impact of missing data, non-compliance and
withdrawals. R statistical software version 3.0.2 (or later; R
Foundation for Statistical Computing, Vienna, Austria)
will be used to analyse data.
Sample size (n = 120) was calculated on the basis of
data derived from our pilot study showing freedom for
AF/AT at 6 months in the surgical group in 76% versus
44% in the catheter group. Using these results a sample
size of 48 per group will be required to detect a differ-
ence in the primary outcome with 90% power and a 5%
significance level. There is a margin of error of 25%,
which includes a 10% dropout rate.
The primary outcome of the trial is the proportion of pa-
tients with LSPAF undergoing ablation who are free from
atrial arrhythmias (defined as a single episode of ≥ 30 s)
within 1 year after a single ablation procedure. ‘Arrhythmia-
free’ patients will be identified through ILR data assessments
performed monthly by a single blinded cardiac physiologist.
Chi-square tests will be used for comparisons between the
trial arms. A logistic regression model will be developed to
estimate the probability of being free from AF at 1 year by
either procedure. The primary measure to be reported is the
OR of being ‘AF-free’ for the surgical group after the other
factors in the model have been controlled for. The recur-
rence of AF and duration of AF freedom will be analysed
using Kaplan-Meier survival curves.
Binary secondary outcomes (reduction in arrhythmia
burden, freedom from arrhythmia following multiple
procedures) will be analysed in the same manner as the
primary outcome using a combination of chi-square
tests and logistic regression. Freedom from arrhythmia
following multiple procedures will be analysed using
Kaplan-Meier survival curves.
Continuous data will be analysed using either Student’s
t test or the Mann-Whitney U test and presented as
mean ± SD, mean (95% CI) or median (IQR), depending
upon distribution of obtained data. P < 0.05 will be con-
sidered significant.
Table 3 Known complications associated with ablative
procedures in Catheter Ablation versus Thoracoscopic Surgical
Ablation in Long Standing Persistent Atrial Fibrillation study
Adverse events Serious adverse events
Bruising, hematoma, vascular
injury not requiring intervention
Vascular complications requiring
blood transfusion or intervention
Pericardial/pleural effusion
(observation only)
Symptomatic pericardial/pleural
effusion or requiring intervention
Broken rib Stroke/transient ischemic attack
Pneumothorax requiring
observation
Pneumothorax requiring chest drain
Infection (i.e., pneumonia) Empyema
Pulmonary oedema Myocardial infarction
Temporary phrenic
nerve damage
Permanent phrenic nerve damage
Pain near surgical sites Pulmonary vein stenosis (> 50%
reduction in diameter from baseline)
Requirement to insert PPM (with or
without prior conduction tissue damage)
Cardiac trauma requiring surgical
intervention
Radiation-induced skin damage
Oesophageal atrial fistula
Death
PPM Permanent pacemaker
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Health economic analysis
Cost-effectiveness will be assessed using both trial-based
and model-based health economic analyses. Both will
follow international methodological guidelines [67–70]
and the ‘reference case’ recommended by the National
Institute for Health and Care Excellence (NICE) for use
in its technology appraisals [71–74], including the use of
an NHS and personal social services perspective for
costing and discounting of costs and QALYs at an
annual rate of 3.5%.
In the trial-based analysis we will use EQ-5D-5L and
health and social care resource use data to estimate the
costs and QALYs accrued over the 12-month follow-up
period by trial participants. In our main analysis we will
include costs for all health and social care recorded in
the eCRF and reported by patients in the health eco-
nomics questionnaire at 3, 6, 9 and 12 months. The unit
costs of services will be based on national average esti-
mates from published sources [75–78]. We will also con-
duct a sensitivity analysis including only costs judged by
the research team to be potentially related to AF or to
AF treatment. QALYs will be estimated from survival
data and quality of life (EQ-5D-5L) scores at 0, 3, 6, 9
and 12 months using an AUC approach. EQ-5D-5L
scores will be calculated using the 2016 value set for
England [79]. Mean between-group differences in
QALYs and costs will be estimated using a bivariate
regression approach, taking account of correlations
between costs and effects and adjusting for any baseline
differences in EQ-5D-5L scores or other key patient
characteristics (such as age, CHA2DS2VASc score
[congestive heart failure {or left ventricular systolic
dysfunction}, hypertension {blood pressure consistently
> 140/90 mmHg or treated hypertension on medication},
age ≥ 75 years, diabetes mellitus, prior stroke or transient
ischaemic attack or thromboembolism, vascular disease
{e.g., peripheral artery disease, myocardial infarction,
aortic plaque}, age 65–74 years, sex category {i.e., female
sex}] or HAS-BLED score [hypertension, abnormal
renal/liver function, stroke, bleeding history or predis-
position, labile international normalised ratio, elderly,
drugs/alcohol concomitantly]). Multiple imputations
will be used to account for missing data if appropri-
ate [39, 65, 69, 80]. If the results indicate a trade-off
between costs and health effects, an incremental cost-
effectiveness ratio will be calculated—the ‘cost per QALY’.
The extent of uncertainty over the results will be esti-
mated using bootstrap regression and presented in the
form of a cost-effectiveness acceptability curve [81].
A model-based economic analysis will also be con-
ducted to estimate long-term benefits, harms and costs
of surgical and catheter ablation compared with AAD
therapy in patients with LSPAF. This will extrapolate
costs and health outcomes observed in the trial,
including freedom from arrhythmia, utility (EQ-5D-5L
scores) and incidence of major side effects, over a long
time horizon (up to lifetime). The model will also allow
us to estimate costs and outcomes for the trial partici-
pants under medical management, which will provide
further information about the comparative cost-
effectiveness of treatment options for this patient group
for healthcare commissioners and research funders. The
model will be based on the MAPGuide AF model [82].
This is a discrete event simulation which estimates life-
time costs and QALYs for a heterogeneous population of
individuals with AF treated according to a defined
pathway of care, including anti-thrombotic and AAD
therapy. The base case version of the model reflects the
recommended care pathway in the NICE clinical guide-
line for AF. This care pathway can be changed to esti-
mate costs and QALYs associated with different
treatments (e.g., catheter ablation, thoracoscopic surgical
ablation or AAD).
Discussion
The use of traditional pharmacological agents to treat
LSPAF is not satisfactory, owing to their serious side
effects and need for lifelong treatment. Catheter ablation
is widely accepted and effective therapy for paroxysmal
AF, but its effectiveness in patients with LSPAF is
limited, and multiple ablations may be required to
relieve patients of symptoms [83–86]. On the basis of
the encouraging results of thoracoscopic surgical abla-
tion in several cohort studies of subjects with persistent
AF and LSPAF and our pilot study [45, 87, 88], we have
designed this trial to compare the two ablative treat-
ments and provide first-class evidence of their efficacy,
safety and cost-effectiveness.
Trial status
The trial was open to recruitment on 1 August 2015 and
currently is actively recruiting at two three NHS special-
ist care centres (Royal Brompton and Harefield NHS
Foundation Trust, Brighton and Sussex University Hos-
pitals NHS Trust and Liverpool Heart and Chest NHS
Foundation Trust). Ashford and St Peter’s Hospitals
NHS Trust is also registered as a patient identification
centre.
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